Mini Review
LRRK2 Signalling Pathways in Parkinson’s Disease
Received Date:January 08, 2019; Published Date: January 16, 2019
Abstract
Parkinson’s disease (PD) is a common neurodegenerative disorder with the pathological hallmark of progressive loss of dopamine neurons in affected brains. There is no cure for PD and current therapy does not halt the underlying degenerative process. The pathogenesis of PD is not fully understood but is likely caused by a combination of genetic and environmental factors. Several genes are associated with the onset and progression of familial PD. Mutations in LRRK2 are the most frequent known cause of lateonset PD. Many studies have been conducted to elucidate the functions of LRRK2 and identify effective LRRK2 inhibitors for PD treatment. In this review, I discuss the role of LRRK2 in PD and recent progress in studying LRRK2 cellular functions and the use of LRRK2 inhibitors as therapeutic agents.
-
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
